Long non‐coding RNA ANRIL interacts with microRNA‐34a and microRNA‐125a, and they all correlate with disease risk and severity of Parkinson's disease

Yang, Peng; Lin, Guiqing; Wang, Minli; Chen, Xuewei; Huang, Jian

doi:10.1002/jcla.24037

Cited by 12 publications

(9 citation statements)

References 46 publications

(63 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most frequent etiology of PD reported was idiopathic/sporadic (n = 29 studies) 30 , 37 , 39 , 41 , 44 , 45 , 48 , 49 , 58 , 62 , 64 , 68 , 70 , 77 – 79 , 86 , 88 , 94 , 96 , 101 , 110 – 112 , 121 , 122 , 126 , 128 , 129 PD patients were commonly receiving medical and/or surgical antiparkinsonian treatment at time of inclusion (n = 35 studies) 8 , 29 , 37 , 38 , 43 , 45 , 47 , 48 , 51 , 54 , 56 , 58 , 63 , 77 – 80 , 83 , 90 , 99 , 100 , 103 – 107 , 109 , 110 , 122 – 125 , 127 , 129 , 132 . Of these, Soreq et al included patients who were on PD medications and subthalamic nucleus deep brain stimulation (STN-DBS0 56 .…”

Section: Resultsmentioning

confidence: 99%

“…Of the studies which did report these data, the United Kingdom Parkinson’s Disease Society Brain Bank Criteria (UKPDSBBC) was the most frequently used diagnostic criteria (n = 48 studies) 8 , 10 , 30 , 31 , 35 , 39 , 44 , 45 , 47 – 51 , 53 , 54 , 58 – 60 , 62 , 64 – 68 , 70 , 75 , 80 – 82 , 85 , 86 , 89 , 91 , 95 , 98 , 104 , 107 – 110 , 112 , 117 , 118 , 121 , 124 , 125 , 128 , 129 . Other clinical criteria used were the Gelb (n = 5 studies), 29 , 103 , 105 , 106 , 126 the Queen Square Brain Bank (n = 2 studies), 42 , 94 and the Movement Disorders Society (MDS) criteria (n = 13 studies) 32 , 36 , 38 , 41 , 46 , 61 , 71 , 76 – 79 , 122 , 132 . The study by Shu et al .…”

Section: Resultsmentioning

confidence: 99%

“…For example, downregulation of miR-133b has been demonstrated in PD brains. This miRNA is postulated to play a role in PD by regulating the transcription factor Pitx3, involved in dopamine neuron development 79 , 113 . This miRNA has also been shown to be downregulated in the plasma and serum of PD patients 43 , 44 , 82 Therefore, the clustering of several related pathways highlights the potential of peripheral biofluid miRNAs to both identify those at risk of developing PD and to further our understanding of CNS pathologies.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

MicroRNAs in Parkinson’s disease: a systematic review and diagnostic accuracy meta-analysis

Guévremont,

Roy,

Cutfield

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Current clinical tests for Parkinson’s disease (PD) provide insufficient diagnostic accuracy leading to an urgent need for improved diagnostic biomarkers. As microRNAs (miRNAs) are promising biomarkers of various diseases, including PD, this systematic review and meta-analysis aimed to assess the diagnostic accuracy of biofluid miRNAs in PD. All studies reporting data on miRNAs expression in PD patients compared to controls were included. Gene targets and significant pathways associated with miRNAs expressed in more than 3 biofluid studies with the same direction of change were analyzed using target prediction and enrichment analysis. A bivariate model was used to calculate sensitivity, specificity, likelihood ratios, and diagnostic odds ratio. While miR-24-3p and miR-214-3p were the most reported miRNA (7 each), miR-331-5p was found to be consistently up regulated in 4 different biofluids. Importantly, miR-19b-3p, miR-24-3p, miR-146a-5p, and miR-221-3p were reported in multiple studies without conflicting directions of change in serum and bioinformatic analysis found the targets of these miRNAs to be associated with pathways important in PD pathology. Of the 102 studies from the systematic review, 15 studies reported sensitivity and specificity data on combinations of miRNAs and were pooled for meta-analysis. Studies (17) reporting sensitivity and specificity data on single microRNA were pooled in a separate meta-analysis. Meta-analysis of the combinations of miRNAs (15 studies) showed that biofluid miRNAs can discriminate between PD patients and controls with good diagnostic accuracy (sensitivity = 0.82, 95% CI 0.76–0.87; specificity = 0.80, 95% CI 0.74–0.84; AUC = 0.87, 95% CI 0.83–0.89). However, we found multiple studies included more males with PD than any other group therefore possibly introducing a sex-related selection bias. Overall, our study captures key miRNAs which may represent a point of focus for future studies and the development of diagnostic panels whilst also highlighting the importance of appropriate study design to develop representative biomarker panels for the diagnosis of PD.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

MicroRNAs in Parkinson’s disease: a systematic review and diagnostic accuracy meta-analysis

Guévremont,

Roy,

Cutfield

et al. 2023

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Dysregulation of miR-34a was observed in ALS (Raheja et al, 2018;Rizzuti et al, 2018;Kmetzsch et al, 2021), PD (Grossi et al, 2021;Yang et al, 2022), AD (Sarkar et al, 2016;Cosín-Tomás et al, 2017;Li and Cai, 2021), HD (Reynolds et al, 2018), and MS (Ghadiri et al, 2018). In AD, hsa-miR-34a was overexpressed in specific brain regions (Sarkar et al, 2016;Li and Cai, 2021), but downregulated in blood or CSF (Cosín-Tomás et al, 2017;.…”

Section: Hsa-mir-34amentioning

confidence: 99%

Shared miRNA landscapes of COVID-19 and neurodegeneration confirm neuroinflammation as an important overlapping feature

Trampuž

Vogrinc

Goričar

et al. 2023

Front. Mol. Neurosci.

View full text Add to dashboard Cite

IntroductionDevelopment and worsening of most common neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis, have been associated with COVID-19 However, the mechanisms associated with neurological symptoms in COVID-19 patients and neurodegenerative sequelae are not clear. The interplay between gene expression and metabolite production in CNS is driven by miRNAs. These small non-coding molecules are dysregulated in most common neurodegenerative diseases and COVID-19.MethodsWe have performed a thorough literature screening and database mining to search for shared miRNA landscapes of SARS-CoV-2 infection and neurodegeneration. Differentially expressed miRNAs in COVID-19 patients were searched using PubMed, while differentially expressed miRNAs in patients with five most common neurodegenerative diseases (Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis, and multiple sclerosis) were searched using the Human microRNA Disease Database. Target genes of the overlapping miRNAs, identified with the miRTarBase, were used for the pathway enrichment analysis performed with Kyoto Encyclopedia of Genes and Genomes and Reactome.ResultsIn total, 98 common miRNAs were found. Additionally, two of them (hsa-miR-34a and hsa-miR-132) were highlighted as promising biomarkers of neurodegeneration, as they are dysregulated in all five most common neurodegenerative diseases and COVID-19. Additionally, hsa-miR-155 was upregulated in four COVID-19 studies and found to be dysregulated in neurodegeneration processes as well. Screening for miRNA targets identified 746 unique genes with strong evidence for interaction. Target enrichment analysis highlighted most significant KEGG and Reactome pathways being involved in signaling, cancer, transcription and infection. However, the more specific identified pathways confirmed neuroinflammation as being the most important shared feature.DiscussionOur pathway based approach has identified overlapping miRNAs in COVID-19 and neurodegenerative diseases that may have a valuable potential for neurodegeneration prediction in COVID-19 patients. Additionally, identified miRNAs can be further explored as potential drug targets or agents to modify signaling in shared pathways.Graphical AbstractShared miRNA molecules among the five investigated neurodegenerative diseases and COVID-19 were identified. The two overlapping miRNAs, hsa-miR-34a and has-miR-132, present potential biomarkers of neurodegenerative sequelae after COVID-19. Furthermore, 98 common miRNAs between all five neurodegenerative diseases together and COVID-19 were identified. A KEGG and Reactome pathway enrichment analyses was performed on the list of shared miRNA target genes and finally top 20 pathways were evaluated for their potential for identification of new drug targets. A common feature of identified overlapping miRNAs and pathways is neuroinflammation. AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; COVID-19, coronavirus disease 2019; HD, Huntington’s disease; KEGG, Kyoto Encyclopedia of Genes and Genomes; MS, multiple sclerosis; PD, Parkinson’s disease.

show abstract

“…Additionally, increased expression of MALAT1 has been observed in AF patients and is implicated in the development of AF by modulating apoptosis and cardiomyocyte superoxide dismutase expression, among other mechanisms [82]. Another lncRNA, ANRIL, which is associated with cardiovascular disease, exhibits upregulated expression in AF patients and can influence the onset and progression of AF by affecting the expression of ion channels, among other pathways [83,84]. Conversely, FENDRR expression levels are significantly down-regulated in AF patients, and its overexpression has been found to substantially inhibit AF development [85].…”

Section: Atrial Fibrillation (Af)mentioning

confidence: 99%

Review:Research status of cardiovascular and cerebrovascular diseases and non-coding RNA

Jiang¹,

Hu²

2023

Clin. transl. rep.

View full text Add to dashboard Cite

Cardiovascular and cerebrovascular diseases (CVD) encompass a range of conditions affecting the heart, brain, and blood vessels, including coronary heart disease, hypertension, and stroke. In recent years, there has been growing evidence highlighting the significant role of non-coding RNAs (ncRNAs) in the development and progression of cardiovascular diseases. Among the various types of ncRNAs, long-stranded non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) have emerged as prominent players in cardiovascular research. Advancements in technology and in-depth research have revealed that ncRNAs and circRNAs exert regulatory effects on the biological functions of the cardiovascular system through various pathways. For instance, they can modulate the proliferation, migration, and apoptosis of vascular endothelial cells, as well as regulate cardiac muscle contraction and cardiomyocyte apoptosis. Additionally, ncRNAs and circRNAs can influence downstream targets and pathways involved in cardiovascular diseases. The exploration of ncRNAs and circRNAs in cardiovascular research has opened up new avenues for the diagnosis and treatment of CVDs. By understanding the intricate regulatory mechanisms mediated by these non-coding RNAs, researchers have gained valuable insights into the pathogenesis of cardiovascular diseases and identified potential therapeutic targets. Consequently, these studies have provided novel ideas and approaches for the diagnosis, prevention, and management of CVDs.

show abstract

Long non‐coding RNA ANRIL interacts with microRNA‐34a and microRNA‐125a, and they all correlate with disease risk and severity of Parkinson's disease

Cited by 12 publications

References 46 publications

MicroRNAs in Parkinson’s disease: a systematic review and diagnostic accuracy meta-analysis

MicroRNAs in Parkinson’s disease: a systematic review and diagnostic accuracy meta-analysis

Shared miRNA landscapes of COVID-19 and neurodegeneration confirm neuroinflammation as an important overlapping feature

Review:Research status of cardiovascular and cerebrovascular diseases and non-coding RNA

Contact Info

Product

Resources

About